VITRAKVI

This brand name is authorized in Austria, Brazil, Canada, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Turkey, United Kingdom, United States

Active ingredients

The drug VITRAKVI contains one active pharmaceutical ingredient (API):

1 Larotrectinib UNII PF9462I9HX - LAROTRECTINIB

Larotrectinib is an adenosine triphosphate (ATP)-competitive and selective tropomyosin receptor kinase (TRK) inhibitor. The TRK family of proteins, TRKA, TRKB, and TRKC, is encoded by NTRK1, NTRK2 and NTRK3 genes. Larotrectinib was rationally designed to avoid activity with off-target kinases. It is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. Read about Larotrectinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VITRAKVI Oral solution	European Medicines Agency (EU)	MPI, EU: SmPC
VITRAKVI Capsule / Oral solution	FDA, National Drug Code (US)	MPI, US: SPL/PLR
VITRAKVI Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX12		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 538920030030007, 538920030030107, 538920040030407
Country: CA	Health Products and Food Branch	Identifier(s): 02490315, 02490323, 02490331
Country: EE	Ravimiamet	Identifier(s): 1801145, 1801156, 1801167
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 167776, 429452, 499084
Country: FR	Base de données publique des médicaments	Identifier(s): 64373909, 65942815, 67022406
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 377474, 392356, 392359
Country: HK	Department of Health Drug Office	Identifier(s): 66491, 66492, 66493
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8549, 8737
Country: IT	Agenzia del Farmaco	Identifier(s): 048215014, 048215026, 048215038, 048215040
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291071M1029, 4291071M2025, 4291071S1028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088495, 1088496, 1088497, 1092623
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 206156, 206164, 206172
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100426670, 100426718, 100426760
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699546156382, 8699546156399, 8699546650040
Country: US	FDA, National Drug Code	Identifier(s): 50419-390, 50419-391, 50419-392, 71777-390, 71777-391, 71777-392